Based on the Achilles Therapeutics PLC ADR stock forecast from 0 analysts, the average analyst target price for Achilles Therapeutics PLC ADR is not available over the next 12 months. Achilles Therapeutics PLC ADR’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Achilles Therapeutics PLC ADR is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, Achilles Therapeutics PLC ADR’s stock price was USD 1.14. Achilles Therapeutics PLC ADR’s stock price has changed by +18.13% over the past week, +6.54% over the past month and +38.97% over the last year.
No recent analyst target price found for Achilles Therapeutics PLC ADR
No recent average analyst rating found for Achilles Therapeutics PLC ADR
Company Overview Achilles Therapeutics PLC ADR
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom. Read Less
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to ide...Read More
Frequently Asked Questions About Achilles Therapeutics PLC ADR (ACHL) Stock
Stock Target Advisor's fundamental analysis for Achilles Therapeutics PLC ADR's stock is Slightly Bearish.
Unfortunately we do not have enough data on ACHL's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ACHL's stock to indicate what its average analyst target is.
ACHL stock's Price/Earning ratio is 0.17.
Our analysis grades ACHL stock's Price / Earning ratio at B. This means that ACHL stock's Price/Earning ratio is above 17% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ACHL may be undervalued for its sector.
The last closing price of ACHL's stock was USD 1.14.
The most recent market capitalization for ACHL is USD 0.04B.
Unfortunately we do not have enough analyst data on ACHL's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Achilles Therapeutics PLC ADR's stock.
As per our most recent records Achilles Therapeutics PLC ADR has 204 Employees.
Achilles Therapeutics PLC ADR's registered address is 245 Hammersmith Road, London, United Kingdom, W6 8PW.
You can get more information about it from Achilles Therapeutics PLC ADR's website at https://www.achillestx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Achilles Therapeutics PLC ADR (ACHL) Stock
Stock Target Advisor's fundamental analysis for Achilles Therapeutics PLC ADR's stock is Slightly Bearish.
Unfortunately we do not have enough data on ACHL's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ACHL's stock to indicate what its average analyst target is.
ACHL stock's Price/Earning ratio is 0.17.
Our analysis grades ACHL stock's Price / Earning ratio at B. This means that ACHL stock's Price/Earning ratio is above 17% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ACHL may be undervalued for its sector.
The last closing price of ACHL's stock was USD 1.14.
The most recent market capitalization for ACHL is USD 0.04B.
Unfortunately we do not have enough analyst data on ACHL's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Achilles Therapeutics PLC ADR's stock.
As per our most recent records Achilles Therapeutics PLC ADR has 204 Employees.
Achilles Therapeutics PLC ADR's registered address is 245 Hammersmith Road, London, United Kingdom, W6 8PW.
You can get more information about it from Achilles Therapeutics PLC ADR's website at https://www.achillestx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ACHL !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
